NAGE

Study Overview: Niagen Biosciences conducted a randomized controlled trial on its nicotinamide riboside (NR) supplement, Niagen, to evaluate its effects on individuals suffering from long COVID symptoms, with 58 participants receiving either the supplement or a placebo.

Results and Findings: While the primary endpoint was not statistically significant, participants taking Niagen NR reported improvements in fatigue, sleep quality, and mood, with NAD+ levels increasing significantly, indicating potential benefits in addressing long COVID.

Safety and Tolerability: The Niagen NR supplement was well tolerated among participants, showing no significant difference in adverse events compared to the placebo group, suggesting a favorable safety profile.

Future Research Plans: Niagen Biosciences aims to further investigate NAD+ biology and its therapeutic potential for post-viral recovery, with plans for larger studies to validate the initial findings from this trial.

Clinical Trial Findings: A clinical trial published in The Lancet showed that daily supplementation with Niagen® significantly increased NAD+ levels and improved symptoms such as fatigue, depression, and sleep quality in individuals with long COVID.

Study Overview: The randomized, double-blind, placebo-controlled study involved 58 participants and demonstrated within-group improvements in cognitive performance and other symptoms, although no statistically significant differences were found between the Niagen and placebo groups.

Importance of NAD+: The study highlights the potential role of NAD+ restoration in addressing long COVID symptoms, suggesting that it may help restore biological pathways affected by the condition, including mitochondrial function and cellular repair.

Future Research Directions: While the findings are promising, further large-scale studies are needed to confirm the results and better understand the therapeutic potential of NAD+ in post-viral recovery and energy metabolism.